Halozyme Therapeutics has had a sharply different week from the one the previous note described — the put-heavy options spike has reversed, shorts are trimming, and the stock has added 8.4% to close at $115.13.
The clearest reversal is in options. The put/call ratio collapsed to 0.29 on Tuesday and held near that level through Monday's close — the lowest end of the 52-week range, which bottoms at 0.21. That is the mirror image of last week's defensive posture. The episodic put-buying clusters that dominated the prior note (PCR spiking above 2.0 on September 8, September 15, and September 16) have given way to call-heavy flow, suggesting the options market has flipped from hedging to directional participation in the rally. The z-score of -0.60 confirms the reading is below the 20-day mean of 0.78, though the mean itself is distorted by those prior spikes.
Short positioning has shifted direction, though the structural story remains intact. Short interest dipped 1.1% on the week to 12.3% of the free float — down from the September 15 peak of roughly 12.5% but still elevated relative to the mid-August base near 11.6%. The borrow market has stayed relaxed throughout: cost to borrow is running at just 0.55%, and availability is at 290%, meaning nearly three shares remain available to lend for every one already borrowed. That is comfortably within normal range and well above the 52-week tightest point of 177%. The short score has eased slightly to 65.8 from 67.5 a week ago — the direction of travel is consistent with modest covering rather than a forced unwind.
The Street's tone supports the move. Following August's blowout quarter — a one-day gain of 23% — analysts reset targets upward across the board. Leerink Partners upgraded to Outperform from Market Perform and lifted its target from $83 to $110. TD Cowen and Wells Fargo also raised targets. The stock has since traded through several of those revised numbers; at $115.13, it is now above the HC Wainwright Buy target of $115 and comfortably above the Wells Fargo Equal-Weight target of $95. The consensus remains a Buy, and the forward EPS trajectory is strong — the 12-month forward earnings growth factor ranks in the 93rd percentile. EV/EBITDA has drifted to 11.1x, up modestly over the past week, while the P/E at 11.6x reflects a relatively undemanding multiple for the growth on offer.
Institutional ownership adds texture. BlackRock holds just over 11.7% of shares and added 197,000 shares through August. State Street and Invesco also added in the same period. On the insider side, all recent trades are under pre-arranged 10b5-1 plans — CEO Helen Torley exercised options and sold shares on September 10-11, and director Matthew Posard sold across four tranches on September 16. The 90-day net is a $15.8 million outflow by value. Planned sales carry less signal than discretionary ones, but the volume is worth noting as the stock approaches new highs.
Among closely correlated peers, RCEL rose 12.5% on the week and NTRA added 11.4%, suggesting the bid was broader than HALO alone. BMRN was the exception, slipping 1.7%. The next scheduled event is a Q3 earnings release on October 27 — the last print moved the stock 23% in a single session, so positioning in the weeks ahead is likely to reflect how much of that enthusiasm has now been priced in at $115.
See the live data behind this article on ORTEX.
Open HALO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
